Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.
Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.
A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.
Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.
Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.
Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.
For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.
Codexis (CDXS) and Molecular Assemblies announced advancements in their partnership focused on Fully Enzymatic Synthesis™ (FES™) technology, utilizing Codexis’ engineered enzymes for enhanced DNA synthesis. The collaboration has produced a refined version of terminal deoxynucleotidyl transferase (TdT) polymerase, which improves synthesis accuracy and efficiency. A Key Customer Program will begin later this year, allowing select clients access to long, custom oligonucleotides. FES technology aims to disrupt traditional chemical methods, streamlining synthetic biology applications.
Codexis (Nasdaq:CDXS), an enzyme engineering company, announced participation in the Cowen 42nd Annual Health Care Conference set for March 7-9, 2022. Management will engage in a panel discussion titled “Synthetic Biology Enabling Discovery” on March 8 at 3:30 p.m. ET, followed by a fireside chat on March 9 at 1:30 p.m. ET. Both sessions will be webcasted and accessible in the Investor Relations section of the Codexis website for 30 and 90 days post-event. The company focuses on advancing synthetic biology through innovative enzyme solutions.
Codexis reported a record total revenue of $104.8 million for 2021, marking a 52% increase from 2020 and achieving its eighth consecutive year of revenue growth. Product revenues more than doubled to $70.7 million, driven primarily by sales to Pfizer for the COVID-19 drug PAXLOVID™. The company projects 2022 total revenues between $152 million and $158 million, reflecting anticipated continued growth. Despite increased R&D and SG&A expenses, Codexis maintains a solid cash position of $116.8 million.
Codexis (Nasdaq:CDXS) announced it will report its fourth quarter and fiscal year 2021 financial results on February 24, 2022, after market close. A conference call and webcast for discussing the results will be held at 4:30 p.m. ET. Participants can join the live call by dialing 877-705-2976 (domestic) or (201) 689-8798 (international). The webcast will be available for archiving for 90 days. Codexis leverages its proprietary CodeEvolver platform for novel enzyme development impacting various industries.
Codexis (NASDAQ: CDXS) announced that the FDA has granted orphan drug designation and rare pediatric disease designation for its drug candidate CDX-6512, aimed at treating homocystinuria. This enzyme therapy is in pre-IND development and is positioned as a first-in-class oral treatment. The orphan designation provides incentives such as tax credits and potential marketing exclusivity for seven years upon FDA approval. Preclinical data showcasing CDX-6512 was previously presented at the ICIEM in November 2021.
Codexis, a prominent enzyme engineering company, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, scheduled from January 10-13, 2022. The event will take place virtually, allowing investors and interested parties to access a webcast starting January 10 at 7:00 a.m. ET. This presentation will be archived for 90 days on the company's website. Codexis utilizes its CodeEvolver® platform to enhance enzyme performance across pharmaceuticals, food, and industrial applications, showcasing its commitment to sustainable practices and health improvements.
Codexis, a prominent enzyme engineering company, announced the launch of its Codex® HiTemp Reverse Transcriptase, designed for one-step quantitative reverse transcription PCR (RT-qPCR) applications. This enzyme addresses critical challenges in viral diagnostics, including those for SARS-CoV-2. Key features include enhanced thermostability up to 70°C, improved robustness against clinical sample degradation, and a rapid turnaround time of five minutes for reverse transcription reactions. The enzyme is now available for bulk supply, supporting the ongoing demand for efficient viral RNA detection.
Codexis, Inc. (NASDAQ: CDXS) announced key advancements in biotherapeutic programs targeting homocystinuria (HCU) and maple syrup urine disease (MSUD) at the 14th International Congress of Inborn Errors of Metabolism in Sydney. CDX-6512 demonstrated up to 45% suppression of serum homocysteine in HCU mice, while a leucine decarboxylase showed similar results in MSUD models. Codexis aims to develop these gastrointestinal-stable enzymes as oral therapies, potentially improving treatment options for patients constrained by dietary restrictions. The company remains optimistic about further clinical advancements.
Codexis, a leading enzyme engineering company, announced participation in three upcoming virtual investment conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference features an on-demand fireside chat starting November 22, 2021, at 10:00 a.m. ET. The Stephens Annual Investment Conference will host its fireside chat on November 29, 2021, at 2:00 p.m. ET, followed by the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 4:45 p.m. ET. Webcasts will be available for 30 days on the company’s website.
Codexis (Nasdaq:CDXS) announced key presentations at the 14th International Congress of Inborn Errors of Metabolism 2021, highlighting potential treatments for homocystinuria and maple syrup urine disease. The oral presentations will take place on November 21, 2021, featuring CDX-6512, a methionine-gamma-lyase enzyme therapy for homocystinuria, and a bacterial leucine decarboxylase therapy for maple syrup urine disease. Both will be presented by Dr. Kristen Skvorak, emphasizing innovative drug development efforts by Codexis to leverage synthetic biology.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What does Codexis, Inc. specialize in?
How does Codexis generate revenue?
What industries benefit from Codexis’ products and services?
What is the CodeEvolver® technology platform?
Where does Codexis derive its revenue from geographically?
What recent collaborations has Codexis entered into?
What is the significance of Codexis’ strategic collaborations?
What recent achievements has Codexis made in biotherapeutics?
How does Codexis ensure the quality of its products?
How can I stay updated with Codexis’ latest news and developments?
